HC Wainwright lowered shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a buy rating to a neutral rating in a research note released on Monday morning, BenzingaRatingsTable reports.
Other equities analysts have also recently issued reports about the company. Cowen restated a buy rating on shares of Trillium Therapeutics in a report on Thursday, August 15th. Zacks Investment Research upgraded Trillium Therapeutics from a hold rating to a buy rating and set a $0.25 price target on the stock in a report on Saturday, August 17th.
Trillium Therapeutics stock opened at $0.29 on Monday. The stock has a market capitalization of $7.83 million, a price-to-earnings ratio of -0.12 and a beta of 2.20. Trillium Therapeutics has a 52-week low of $0.24 and a 52-week high of $6.75. The stock’s 50 day moving average price is $0.33 and its two-hundred day moving average price is $0.58.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.